JP2006508979A5 - - Google Patents

Download PDF

Info

Publication number
JP2006508979A5
JP2006508979A5 JP2004553551A JP2004553551A JP2006508979A5 JP 2006508979 A5 JP2006508979 A5 JP 2006508979A5 JP 2004553551 A JP2004553551 A JP 2004553551A JP 2004553551 A JP2004553551 A JP 2004553551A JP 2006508979 A5 JP2006508979 A5 JP 2006508979A5
Authority
JP
Japan
Prior art keywords
heteroaryl
aryl
heterocyclyl
arylalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004553551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006508979A (ja
JP4611745B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/035670 external-priority patent/WO2004046101A2/en
Publication of JP2006508979A publication Critical patent/JP2006508979A/ja
Publication of JP2006508979A5 publication Critical patent/JP2006508979A5/ja
Application granted granted Critical
Publication of JP4611745B2 publication Critical patent/JP4611745B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004553551A 2002-11-20 2003-11-10 ErbB2及びEGFR阻害剤としてのシアノグアニジン及びシアノアミジン Expired - Fee Related JP4611745B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42754402P 2002-11-20 2002-11-20
PCT/US2003/035670 WO2004046101A2 (en) 2002-11-20 2003-11-10 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors

Publications (3)

Publication Number Publication Date
JP2006508979A JP2006508979A (ja) 2006-03-16
JP2006508979A5 true JP2006508979A5 (enExample) 2006-08-03
JP4611745B2 JP4611745B2 (ja) 2011-01-12

Family

ID=32326558

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004553551A Expired - Fee Related JP4611745B2 (ja) 2002-11-20 2003-11-10 ErbB2及びEGFR阻害剤としてのシアノグアニジン及びシアノアミジン

Country Status (6)

Country Link
EP (1) EP1567506A4 (enExample)
JP (1) JP4611745B2 (enExample)
AU (1) AU2003291394B2 (enExample)
CA (1) CA2506503A1 (enExample)
NZ (1) NZ540092A (enExample)
WO (1) WO2004046101A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
KR20080014144A (ko) * 2003-08-18 2008-02-13 화이자 프로덕츠 인크. erbB2 항암제에 대한 투약 스케쥴
JP2007505101A (ja) * 2003-09-11 2007-03-08 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 放射性標識されたアニリノキナゾリン型化合物ならびに放射線画像化および放射線治療におけるその使用
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
WO2006118749A1 (en) 2005-05-04 2006-11-09 Janssen Pharmaceutica, N.V. Thia-tetraazaacenaphthylene kinase inhibitors
DE102006012251A1 (de) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
CL2007003158A1 (es) * 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
NZ585357A (en) 2007-10-29 2012-02-24 Natco Pharma Ltd Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
JP5721709B2 (ja) * 2009-07-02 2015-05-20 ニューゲン セラピューティクス, インコーポレイテッド リンを含むキナゾリン化合物および使用方法
CA2900652C (en) 2013-02-15 2021-05-04 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
CN107915751A (zh) 2013-02-20 2018-04-17 卡拉制药公司 治疗性化合物和其用途
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
WO2015066482A1 (en) 2013-11-01 2015-05-07 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3402536A4 (en) 2016-01-13 2019-07-03 Hadasit Medical Research Services And Development Limited RADIOACTIVELY MARKED ERLOTINIB ANALOGUES AND USES THEREOF
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324716B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
MX2019002629A (es) 2016-09-08 2019-10-07 Kala Pharmaceuticals Inc Formas cristalinas de compuestos terapéuticos y usos de los mismos.
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
JP7620629B2 (ja) * 2019-12-02 2025-01-23 アカデミア シニカ PDIA4阻害剤及びβ細胞発症機序を阻害し、糖尿病を治療するためのこのPDIA4阻害剤の使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69536015D1 (de) * 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
WO1997030035A1 (en) * 1996-02-13 1997-08-21 Zeneca Limited Quinazoline derivatives as vegf inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
AU3053999A (en) 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
NZ522568A (en) 2000-06-22 2004-12-24 Pfizer Prod Inc Substituted bicyclic derivatives for the treatment of abnormal cell growth

Similar Documents

Publication Publication Date Title
JP2009515988A5 (enExample)
JP2005526076A5 (enExample)
JP2008510828A5 (enExample)
JP2010535722A5 (enExample)
JP2007502295A5 (enExample)
JP2013504593A5 (enExample)
JP2011513410A5 (enExample)
JP2010511721A5 (enExample)
JP2005508905A5 (enExample)
JP2019513778A5 (enExample)
JP2007524696A5 (enExample)
JP2007523139A5 (enExample)
JP2010501478A5 (enExample)
JP2008523069A5 (enExample)
JP2002512243A5 (enExample)
JP2009534468A5 (enExample)
JP2006514691A5 (enExample)
JP2010077137A5 (enExample)
JP2005535586A5 (enExample)
JP2010505011A5 (enExample)
JP2010504286A5 (enExample)
JP2006517976A5 (enExample)
JP2005289914A5 (enExample)
JP2009535462A5 (enExample)
JP2005538944A5 (enExample)